Tue, Jul 22, 2014, 5:20 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Merrimack Pharmaceuticals, Inc. (MACK) Message Board

crkenmore 1 post  |  Last Activity: May 16, 2014 11:23 AM Member since: Aug 28, 2012
  • crkenmore crkenmore May 16, 2014 11:23 AM Flag

    I share your concern on several levels:
    -Four officers selling all in May including Chairman/CEO, CFO, and Chief Business Officer. Some of these may be " programed sales " however the total amount is higher than in the past. Officers do have the flexibility to cancel or postpone planned sales. This is curious that with key clinical data scheduled to be presented at the American Thoracic Society meeting commencing May, none of the key leaders chose to postpone their sales.

    - Short interest as a percentage of float is a very high 14.5%. 10% is considered by many to be the threshold for caution.

    - A well capitalized private company competitor is also presenting data at the same conference. This adds to the uncertainty.

    - The stock is down 4% today with deteriorating technical s, on relatively high confirming volume.

    In summary the risk/reward a current price level's is not favorable. A price closer to $ 32-$ 32.10, provides a better balance between opportunity and risk.

5.89-0.01(-0.17%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.